1 / 29

Diabetes Mellitus

Diabetes Mellitus. Ahmed Al- Naher FY2 Coventry. Case Scenario. 52 male presents to GP with 3/12 lethargy and 2/52 thirsty and drinking more than normal. PMH HTN Drinks alcohol socially, non-smoker BMI 32 Urine Dip: glucose +++ Random Blood Sugar = 13. Contents. Diagnosis Risk Factors

diza
Télécharger la présentation

Diabetes Mellitus

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Diabetes Mellitus Ahmed Al-Naher FY2 Coventry

  2. Case Scenario • 52 male presents to GP with 3/12 lethargy and 2/52 thirsty and drinking more than normal. • PMH HTN • Drinks alcohol socially, non-smoker • BMI 32 • Urine Dip: glucose +++ • Random Blood Sugar = 13

  3. Contents • Diagnosis • Risk Factors • Complications • Investigations • Management • DKA + HONK

  4. Type 1 vs Type 2 • Type 1 = Inability to produce insulin (autoimmune process against beta islet pancreas cells) • Type 2 = insensitivity to insulin over time • Gestational Diabetes = decreased insulin sensitivity during pregnancy • Secondary Diabetes: • Pancreatic Disease/CF/Chronic Pancreaitis/Pancreatic Ca • Steroid use/ antipsychotics/ thiazide diuretics

  5. Diagnosis • Random Glucose >11.1 mmol/L • Fasting Glucose >7 mmol/L • 2x Fasting glucose samples to confirm • Or presence of symptoms • HbA1c >6.5% (48mmol/L) • OGTT – two hour glucose after 75g glucose • IGT = normal fasting glucose and OGTT between 7-11 • IFG = OGTT <7.8 but fasting glucose 6.1 – 6.9

  6. Risk Factors • T1: Family Hx, Caucasian/Scandinavian, Juvenile onset • T2: • High BMI • Physical inactivity • South Asian/Afro-carribean/middle-eastern • Hx of gestational diabetes, IGT, IFG • Steroid use • PCOS • Family Hx

  7. Presentation • Polyuria • Polydipsia • Lethargy • Recurrent infections • Complications • DKA (T1) • HONK (T2)

  8. Presentation - case • 67 male admitted feeling generally unwell, SOB, sweating and lethargic over last 2 days. • He is a known Type 2 diabetic on insulin with PVD, peripheral neuropathy and previous CVA. His BM is 5.6. • ECG showed residual ST elevation in anterior leads with Q wave and reciprocal changes. Echo showed new septalhypokinesia • The patient had no history of chest pain

  9. Complications • Macrovascular: Stroke, MI, PVD • Retinopathy, Xanthelasma, Cataracts, Opthalmoplegia, maculopathy • Peripheral Neuropathy, Diabetic amyotrophy, neuropathic pain, Autonomic neuropathy • Nephropathy • Recurrent infections: Cellulitis, UTI, Thrush

  10. Investigations • Bedside: • Urine Dip: Glucose, ketones, MC+S • BM Stix, Ketone Stix • ECG, BP • Neuro, eye, foot exam • ACR, eGFR, microalbuminuria • Injection sites • Bloods - HbA1c, lactate, pH, U+E, Lipids, LFT, TFT

  11. Managing Risk Factors • Lifestyle – Weight loss, Exercise • Education – DESMOND (Diabetes Education and Self Management for Ongoing and Newly Diagnosed) • Self-Monitoring of BM • Dietician, Low sugar diet • Smoking cessation • Foot Care • Eye screening • BP Control: ACEi, CCB, Diuretic, K sparing • Statins, Fibrates • Aspirin

  12. Oral Hypoglycaemics • Biguanides– increase insulin sensitivity: Metformin • Sulphonylureas: Gliclazide, Glibenclamide • Meglitinides: Repaglinide, Nateglinide • Thiazolidinediones: Pioglitazone • DDP-4 inhibitors: Sitagliptin, Vildagliptin • GLP-1 Agonists: Exenatide, Liraglutide • Orlistat • Ascarbose

  13. Treatment Pathway • 1) Lifestyle Interventions • 2) Metformin • 3) Metformin + sulphonylurea • 4) Metformin + sulphonylurea + Thiazolidinedione or GLP-1 agonist or DDP-4 inhibitor • 4) Metformin + sulphonylurea + insulin • 5) Increase insulin

  14. Insulin Types • Rapid-acting: Lispro (Humalog), Aspart (Novorapid) • Short-acting: Soluble Insulin (Actrapid) • Intermediate Acting: NPH (Insulatard) • Long-acting: Glargine (Lantus), Detemir (Levemir) • Ultra long-acting: Degludec • Pre-mixed: Novomix30, Humalog Mix25, Humumlin M3 • Regimens: • Once Nightly • Twice Daily Biphasic • Basal Bolus • Continuous Pump

  15. Prognosis • T1 = increased risk of blindness, ESRF, CVD • Control of BP, Lipids, BM and weight are prognostic • T2 = 75% die of heart disease 15% die of stroke • Every 1% rise in HbA1c level risk of diabetes related death increases by 21%

  16. Case Scenario • 58 female T2DM, Portuguese, does not speak English, not complying with medication or dietary advice, admitted with hyperglycaemia and seizures. Continues to have high BMs of >25 on wards and wishes to self-discharge. • She has severe retinopathy blindness and PVD and no carers at home. She is prescribed a pre-mix regimen. • What are the obstacles to safe management of this patient? • What services/ support can be arranged?

  17. Medical Emergency: Hypoglycaemia • BM < 3 • Symptoms: low GCS, seizures, clammy, sweaty, tachycardic, behaviour change, slurred speech, shaking • Risk: Strict BM control, Alcohol, malabsorption, Renal failure, medication, lipohypertrophy, hypothyroid • GlucoJuice/Glucotab 10-20g • GlucoGel (Hypostop) • 10% Dexrose IV 150-250ml • Glucagon 1mg IM/SC • Cerebral Oedema: Mannitol, Dexamethasone, 50% Dex

  18. Medical Emergency: DKA • Hyperglycaemia, Ketonaemia, Acidosis • Ketones >3mmol/L • BM >11 • pH <7.3, HCO3 <15 • Triggered by stress: Infection, Poor compliance, endocrine crises, CVD, Alcohol, medication

  19. DKA signs • Polydipsia, polyuria • Weight loss, lethargy • Vomiting, Abdo pain • SOB (Kussmaul’srespiration) • Low GCS, confusion • Dehydration: dry mucus membranes, reduced skin turgor, sunken eyes, slow cap refill, tachycardia, low BP • Pear Drop Breath • Signs of infection: Fever, crackles, cellulitis • Increased osmolality and anion gap

  20. Specific investigations • Serial BMs and Ketones • Serial ABGs or VBGs • Septic Screen: BCM, Urine Dip, CXR • U+E including K • Trop T, CK • ECG • Amylase • CT Head • Monitor BM, Ketones, Acidosis, mental state, fluid status

  21. DKA Resuscitation • Correct dehydration: Fast NaCl 0.9% initially • Fixed Rate insulin infusion: 0.1 unit/kg • Reduce BM ~3/hr to avoid cerebral oedema • Continue baseline long acting insulin • Run with NaCl 0.9% + KCl if <5.5 • 10% glucose once BM <14 • Treat underlying cause • Once E+D convert back to normal insulin + DSN r/w • Indications for ITU: haemodynamic instability, cardiogenic shock, respiratory failure, severe acidosis, coma

  22. Complications • Cerebral oedema: headache, confusion, urinary incontinence, coma – main mortality in children • Hypoglycaemia – arrhythmia, coma • Hypokalaemia – cardiac arrhythmia • VTE • Retinopathy • ARDS/ Pulmonary oedema • Prognosis worsens with age, low GCS

  23. Medical Emergency: HONK • T2DM • Hyperglycaemia, high serum osmolality, no ketosis • Osmotic diuresis -> intracellular dehydration • Triggers: Infection, poor BM control, MI, CVA, endocrine crises, Acute abdo, medication, metformin, alcohol, first presentation • Old age, dementia, steroid use • Severe Dehydration • Low GCS, confusion, seizures • Lethargy, weakness • Abdo Pain, N+V

  24. HONK Mx • Ix as for DKA • Initial Fluid resuscitation • Variable Rate Insulin infusion • Run with 8 hourly NaCl + KCl • Treat underlying cause • Review medication • LMWH

  25. Final Case • 87 yo male from nursing home with known glioblastomamultiforme admitted with worsening confusion, reduced mobility and polyuria. • CT shows no new haemorrhage, infarct or mass effect • DHxfrusemide, aspirin and dexamethasone • pH 7.2 lactate 2.9 BM 32 • Urine: Blood + Leuk + Gluc +++ Nitrites + • Initial management? • Long-term treatment plan?

  26. Questions?

  27. http://integrate.ccretherapeutics.org.au/Calculator/UkPds.aspxhttp://integrate.ccretherapeutics.org.au/Calculator/UkPds.aspx

More Related